FDA Approves Supernus's Qelbree For Treatment Of Attention-deficit Hyperactivity Disorder

·

·

FDA Approves Supernus's Qelbree For Treatment Of Attention-deficit Hyperactivity Disorder

(RTTNews) – Supernus Pharmaceuticals Inc. (SUPN) said that the U.S. Food and Drug Administration approved Qelbree or viloxazine extended-release capsules for the treatment of attention-deficit hyperactivity disorder or ADHD in pediatric patients 6 to 17 …
See Original Article

LinkedIn gives staff week off for well-being

During the week, LinkedIn will provide employees who may feel isolated the option of taking part in daily activities such as volunteering for worthy causes through “random acts of kindness,” according to the company.
See Original Article

Professor, student represent Marietta College at MBAA-International

Grace Johnson is the McCoy Professor of Management and Accounting and Katie McIlroy is a senior economics and political science major from
See Original Article

New details released on crash that killed two children

According to a criminal complaint, Alexis Martinez, 23, was going close to 90 mph when she crashed along I-25 near Menaul. Her friend, Danielle Ortiz, 23, told police they had both been drinking at Martinez’s house when the two got into an argument and Ortiz …
See Original Article

AbbVie : FDA Extends Review Period For SNDA Of Upadacitinib For Treatment Of Atopic Dermatitis

(RTTNews) – AbbVie (ABBV) said Friday that the U.S. Food and Drug Administration has extended the review period for the supplemental New Drug Application (sNDA) for upadacitinib in the treatment of adults and adolescents with moderate to severe atopic …
See Original Article



Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.